Tamanho : 50mg
Synonyms: GR109714X, BCH-189
| Description | Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. |
| In vivo | Lamivudine exhibits selective inhibitory activity against deoxycytidine kinase, an unusual substrate for the non-natural L-isomer of dNTPs preferred by HBV polymerase. The anti-HBV activity of PCV is attributed to the broad substrate specificity of deoxycytidine kinase and an unusual substrate preference of HBV polymerase for the non-natural L-conformation of dNTPs. The anti-HBV efficacy of PCV appears to rely on multiple factors, including optimal phosphorylation (sufficient for antiviral activity but not cytotoxicity), the extended intracellular half-life of PCV-TP, and the ability of PCV-TP to inhibit the initiation of HBV RT as well as its RT and DNA polymerase activities. Combined use of Lamivudine and Cidofovir synergistically inhibits replication of duck hepatitis B virus and is more effective in reducing the persistent covalently closed circular (CCC) DNA form of DHBV than when used separately. In PBMCs, Lamivudine inhibits HIV-1 p24 antigen production with ED50s ranging from 0.07 μM to 0.2 μM. |
| Synonyms | GR109714X, BCH-189 |
| Molecular Weight | 229.26 |
| Formula | C8H11N3O3S |
| Cas No. | 134678-17-4 |
| Smiles | O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1 |
| Relative Density. | 1.73 g/cm3 (Predicted) |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 240 mg/mL (1046.85 mM), Sonication is recommended.  Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: 42 mg/mL (183.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (21.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
